Tennessee is currently home to 1983 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Nashville, Memphis, Knoxville and Chattanooga. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments
NCT06323928
Recruiting
The purpose of this trial is to determine which doses of Lu AG09222 are recommended to help prevent migraines. People who join this trial have already tried 2 to 4 other available medications to prevent their migraines, but these medications have not helped them.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/14/2024
Locations: Internal Medicine and Pediatric Associates of Bristol, PC, Bristol, Tennessee
Conditions: Migraine
Register for Updates
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise
NCT06323174
Recruiting
This study will look at how much CagriSema helps participants with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a "dummy" medicine (also called "placebo") that has no effect on the body. Participants will get either CagriSema or "dummy" medicine. Which treatment participants get is decided by chance. For each participant, the study will last for about one year.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/14/2024
Locations: Holston Medical Group, Kingsport, Tennessee
Conditions: Type 2 Diabetes
Register for Updates
Study of BMS-986393 a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06297226
Recruiting
The purpose of this study is to evaluate the effectiveness and safety of BMS-986393 in participants with relapsed or refractory multiple myeloma.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/14/2024
Locations: Local Institution - 0043, Nashville, Tennessee
Conditions: Multiple Myeloma
Register for Updates
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
NCT06221969
Recruiting
This study will look at how well CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide that doctors may prescribe in some countries. Participants will get either CagriSema or tirzepatide. Which treatment participant get is decided by chance like flipping a coin. Participant will have an equal chance of receiving either dr... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/14/2024
Locations: AM Diabetes And Endocrinology Center, Bartlett, Tennessee
Conditions: Type 2 Diabetes
Register for Updates
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy
NCT06154252
Recruiting
RESET-Myositis: Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Idiopathic Inflammatory Myopathy
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/14/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Idiopathic Inflammatory Myopathy, Dermatomyositis, Anti-Synthetase Syndrome, Immune-Mediated Necrotizing Myopathy
Register for Updates
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
NCT06122077
Recruiting
The PROACT LUNG study is a prospective multi-center observational study to validate a blood-based test for the early detection of lung cancer by collecting blood samples from high-risk participants who will undergo a routine, standard-of-care screening Low-Dose Computed Tomography (LDCT).
Gender:
All
Ages:
50 years and above
Trial Updated:
06/14/2024
Locations: The Jackson Clinic, PA, Jackson, Tennessee
Conditions: Lung Cancer Diagnosis
Register for Updates
Wearable Technology to Evaluate Hyperglycemia and HRV in DMD - Longitudinal Aim
NCT06093100
Recruiting
Duchenne Muscular Dystrophy (DMD) is an X-linked disorder that causes muscle wasting, cardiopulmonary failure, and premature death. Heart failure is a leading cause of death in DMD, but substantial knowledge gaps exist regarding predisposing risk factors. In the general population, hyperglycemia, insulin resistance, and decreased heart rate variability (HRV; reflecting autonomic dysfunction) are associated with cardiomyopathy (CM). It is unclear whether these factors are associated with DMD-CM.... Read More
Gender:
Male
Ages:
10 years and above
Trial Updated:
06/14/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Duchenne Muscular Dystrophy
Register for Updates
IDEAL: Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA)
NCT06060665
Recruiting
To Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects with Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA)
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/14/2024
Locations: Gastro One, Cordova, Tennessee
Conditions: Primary Biliary Cholangitis
Register for Updates
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
NCT06058377
Recruiting
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and c... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/14/2024
Locations: Baptist Memorial Hospital and Cancer Center-Collierville, Collierville, Tennessee
Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma
Register for Updates
A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06046729
Recruiting
This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis suppurativa (HS) for further clinical development. The study will last approximately 62 weeks and may include up to 31 visits.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/14/2024
Locations: International Clinical Research - Tennessee LLC Research), Murfreesboro, Tennessee
Conditions: Hidradenitis Suppurativa
Register for Updates
Nectero EAST System Clinical Study
NCT06001918
Recruiting
The purpose of this randomized clinical trial is to treat patients with small to mid-sized abdominal aortic aneurysms (AAA), maximum diameter of 3.5 cm to 5.0 cm, using a locally delivered, single-dose endovascular treatment. The main question the study aims to answer is to demonstrate efficacy of the product for stabilization of these small to mid-sized AAA.The study will compare the treatment group to the typical standard of care for these patients, surveillance. All subjects will be followed... Read More
Gender:
All
Ages:
Between 21 years and 85 years
Trial Updated:
06/14/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Abdominal Aortic Aneurysm
Register for Updates
TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma
NCT05980598
Recruiting
The purpose of this trial is to evaluate the safety and efficacy of TransCon TLR7/8 Agonist, TransCon IL-2 β/γ, and pembrolizumab given prior to curative intent surgery in treatment of participants with newly diagnosed Stage III/IVA resectable locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC). After surgery, participants will receive local standard-of-care treatment and will be followed for safety, efficacy, and survival for up to 2 years. This trial contains a safety run... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/14/2024
Locations: Ascendis Investigational Site, Knoxville, Tennessee
Conditions: Head and Neck Neoplasms
Register for Updates